[go: up one dir, main page]

WO2013035997A3 - Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt - Google Patents

Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt Download PDF

Info

Publication number
WO2013035997A3
WO2013035997A3 PCT/KR2012/006698 KR2012006698W WO2013035997A3 WO 2013035997 A3 WO2013035997 A3 WO 2013035997A3 KR 2012006698 W KR2012006698 W KR 2012006698W WO 2013035997 A3 WO2013035997 A3 WO 2013035997A3
Authority
WO
WIPO (PCT)
Prior art keywords
tianeptine
preventing
pharmaceutical composition
salt
treating alopecia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/006698
Other languages
French (fr)
Other versions
WO2013035997A2 (en
WO2013035997A9 (en
Inventor
So-Ra Park
Sung-Ki Seo
Mase LEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuhnil Pharmaceutical Co Ltd
Original Assignee
Kuhnil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuhnil Pharmaceutical Co Ltd filed Critical Kuhnil Pharmaceutical Co Ltd
Publication of WO2013035997A2 publication Critical patent/WO2013035997A2/en
Publication of WO2013035997A9 publication Critical patent/WO2013035997A9/en
Publication of WO2013035997A3 publication Critical patent/WO2013035997A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its pharmaceutically acceptable salt as an active ingredient.
PCT/KR2012/006698 2011-09-06 2012-08-23 Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt Ceased WO2013035997A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110089915A KR101136976B1 (en) 2011-09-06 2011-09-06 Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt
KR10-2011-0089915 2011-09-06

Publications (3)

Publication Number Publication Date
WO2013035997A2 WO2013035997A2 (en) 2013-03-14
WO2013035997A9 WO2013035997A9 (en) 2013-05-02
WO2013035997A3 true WO2013035997A3 (en) 2013-07-04

Family

ID=46271078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006698 Ceased WO2013035997A2 (en) 2011-09-06 2012-08-23 Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt

Country Status (2)

Country Link
KR (1) KR101136976B1 (en)
WO (1) WO2013035997A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888542A (en) * 1996-04-24 1999-03-30 Adir Et Compagnie Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
WO2000059511A1 (en) * 1999-04-07 2000-10-12 Adir Et Compagnie Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
EP1138677A1 (en) * 2000-03-31 2001-10-04 Adir Et Compagnie Process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]-thiazepine and application to the synthesis of tianeptine
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888542A (en) * 1996-04-24 1999-03-30 Adir Et Compagnie Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
WO2000059511A1 (en) * 1999-04-07 2000-10-12 Adir Et Compagnie Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
EP1138677A1 (en) * 2000-03-31 2001-10-04 Adir Et Compagnie Process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]-thiazepine and application to the synthesis of tianeptine
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof

Also Published As

Publication number Publication date
WO2013035997A2 (en) 2013-03-14
WO2013035997A9 (en) 2013-05-02
KR101136976B1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
WO2014009833A3 (en) Complement pathway modulators and uses thereof
PL2808325T3 (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
EP2522653A4 (en) Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
WO2014002051A3 (en) Complement pathway modulators and uses thereof
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
WO2013188783A8 (en) Deuterated derivatives of ruxolitinib
WO2014002058A3 (en) Complement pathway modulators and uses thereof
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1206017A1 (en) Complement pathway modulators and uses thereof
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX353024B (en) Phenyl carbamate compounds for use in preventing or treating epilesy.
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
HK1200314A1 (en) R(+)-n-methyl-propargyl-aminoindan
EA201201202A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2012118308A3 (en) Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2011005052A3 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2013074871A3 (en) Humanin analogs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12830044

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12830044

Country of ref document: EP

Kind code of ref document: A2